20 articles
HIIT training studied in 52 men with prostate cancer on active surveillance to evaluate exercise benefits during watchful waiting.
First study tests whether supervised exercise training is safe and beneficial for bladder cancer patients during treatment.
A 10-week supervised strength program targets chronic inflammation and self-efficacy in long-term allogeneic HCT survivors.
A completed pilot trial tested physical therapy and progressive muscle relaxation to preserve function and mood in older adults with advanced lung cancer.
A completed trial examines how structured exercise reshapes body composition and sustains physical activity habits in breast cancer patients post-diagnosis.
A completed Phase 2 trial explores whether low-dose continuous chemotherapy can boost immunotherapy efficacy in advanced lung cancer.
A pilot trial tested a comprehensive physical, mental, and spiritual intervention for cancer survivors, tracking outcomes at 6 months post-program.
Phase 3 trial compared therapeutic vaccine OSE2101 to chemotherapy in 219 lung cancer patients after immunotherapy failure.
A phase 1/2 trial combined mocetinostat and durvalumab in 83 patients with advanced solid tumors and NSCLC.
Researchers tracked immune changes during intensive radiation treatment to optimize cancer therapy and potential immunotherapy combinations.
Phase 2 trial explores whether combining oncolytic virus therapy with immunotherapy can rescue patients whose melanoma progressed on PD-1 blockade.
French researchers test intraperitoneal nivolumab after surgery and heated chemotherapy for advanced ovarian cancer patients.
Eight-week study of weekday-only intermittent fasting in older breast cancer survivors with overweight demonstrates feasibility.
A phase II trial explores whether the amino acid L-arginine, with or without enzyme inhibitors, can improve erectile function and quality of life after prostate cancer radiation therapy.
A randomized Phase 2 trial investigates whether PD-1 inhibitor discontinuation after early response is safe in non-small cell lung cancer.
A completed phase 3 trial compared A+AVD versus ABVD for advanced classical Hodgkin lymphoma, testing whether replacing bleomycin with brentuximab vedotin improves outcomes.
New viral therapy ASP9801 targets solid tumors directly, potentially offering hope for patients with advanced metastatic cancer.
Stanford researchers used smartwatches and blood tests to monitor dangerous side effects during cutting-edge CAR-T cancer treatment.
A phase I/II trial tests SV-BR-1-GM, a whole-cell cancer vaccine, combined with the checkpoint inhibitor retifanlimab in patients with metastatic breast cancer.
A Phase 1/2 trial tests whether combining durvalumab, tremelimumab, and FOLFOX chemotherapy can safely boost immune response in mCRC.
